How will payers manage reimbursement of multiple interchangeable biosimilars?
MAC reimbursement: 10%
Generic non-MAC reimbursement rate: 10%
Brand reimbursement rate: 40%
Specialty drug specific rate: 40%
Average Sales Price (ASP): 0%
Average Manufacturer Price (AMP): 0%
National Average Drug Acquisition Cost (NADAC): 0%
In which area could you or your company most benefit from additional training?
Biosimilars and interchangeability requirements: 46.1%
Dynamics that drive PBM and health plan decisions: 15.4%
Various hurdles a prescription must clear before being dispensed: 15.4%
Changing 340B landscape: 15.4%
Flow of funds and prescriptions through the pharmacy channels: 7.7%
Pharmacy chain initiatives and strategy updates: 0%
In the next 5 years, what outcome is most likely for FDA management of accelerated approvals with subsequent failed confirmatory trials?
Status quo with extended review timelines and limited FDA authority: 64%
Legislative change leading to additional FDA authority and actions: 27%
Increased pharmaceutical manufacturer voluntary actions: 9%
Which drug will change from prescription to OTC first?
Naloxone: 60%
Statins: 0%
Oral Contraceptives: 30%
Influenza Antivirals: 0%
None of the Above: 10%
Which medical condition will benefit the most from digital therapeutics?
How soon will COVID-19 vaccines transition from government funded to commercially available?
Before the end of 2022: 12.5%
First half of 2023: 25%
Second half of 2023: 50%
2024 and beyond: 12.5%
Which term do you use to refer to the process of preparing a new product or NDC for listing in the drug pricing compendia?
Compendia Submission: 64%
New Product Information: 18%
Drug Database Addition: 9%
Drug Price Publication: 9%
Drug File Integration: 0%
Health IT Preparation: 0%
APhA supports the pharmacy profession through a variety of key advocacy issues. Of the following, which of these issues is a top priority for you?
Improving the COVID-19 Test to Treat Initiative: 9%
Pharmacist Provider Status: 61%
Eliminating DIR Fees: 30%
How quickly will the FDB Vela ePrescribing Network be a viable competitor in the market?
Immediately successful: 0%
Within 1 year: 10%
Within 2-5 years: 70%
More than 5 years: 10%
Will not be able to compete: 0%
Will have limited uptake: 10%
How have drug supply shortages in 2022 changed compared to shortages in 2021?
More products impacted: 44%
Same number of products impacted: 44%
Less products impacted: 11%